Trial Data Transparency, Management Blog | TrialAssure

TrialAssure Introduces Enhanced Architectural Techniques to Improve Accuracy, Visibility, Traceability, and Control Across its AI Platform for Pharma and Biotech Innovative application architecture gives users clearer insight into AI responses, improves output reliability, and strengthens data alignment across LINK AI®, ANONYMIZE®, and REGISTRY® CANTON, Mich. (October 7, 2025) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced the launch of its new enhanced content search and sourcing capability, a technical upgrade designed to boost accuracy, transparency, and reliability across its suite of AI-powered tools. This advancement enables a more structured way for artificial intelligence (AI) to interpret, segment, and retrieve information from source documents, enabling users to gain more precise insights and greater control over the content. TrialAssure has introduced an integrated framework that leverages AI Large Language Models (LLMs) to process and manage content more effectively. This framework emphasizes efficient document ingestion and chunking, optimized embedding and indexing, structured information storage, and advanced AI prompt design and engineering. These techniques replace the out-of-the-box indexing and retrieval approaches and improve the visibility and traceability of AI responses, giving users greater confidence and a more efficient approach to generating structured and regulated documents in the life sciences arena. This also creates a more flexible and tailored experience, allowing AI models to separate, label, and group source material with greater specificity. For instance, information used to create clinical narratives can now be isolated by individual trial participants to eliminate cross-contamination and improve document fidelity. “Giving the pharma and biotech industry clarity into how AI reaches its outputs was a technical challenge at first, but it is our usability promise,” said Zach Weingarden, MS, Director of AI Technology & Applications, TrialAssure. “We are focused on raising the standard for how AI can operate transparently in highly regulated environments like life sciences.”

TrialAssure Introduces Enhanced Architectural Techniques to Improve Accuracy, Visibility, Traceability, and Control Across its AI Platform for Pharma and Biotech

by Staff Writer | October 2025

Posted in Blog, News

Read More

Is Now the Time for Pharma and Biotech to Act with AI or Should the Industry Wait for a Better Model? The integration of artificial intelligence (AI) into pharmaceutical and biotechnology workflows has accelerated significantly in recent years. According to peer-reviewed research by the Tufts Center for the Study of Drug Development, et al, more than 65 percent of pharmaceutical and biotechnology companies, contract research organizations (CROs), and data and technology vendors servicing drug developers are piloting or actively using AI tools. However, more than one-third of organizations remain cautious, unsure whether current AI capabilities are mature enough to justify investment or wide-scale adoption. To address these concerns, we spoke with Zach Weingarden, Director of AI Technology and Applications at TrialAssure, about the risks of waiting, the realities of today’s tools, and how to start effectively.

Is Now the Time for Pharma and Biotech to Act with AI or Should the Industry Wait for a Better Model?

by Zach Weingarden | October 2025

Posted in Blog

Read More

TrialAssure & Certara Joint Webinar: Authoring Clinical Documents with Downstream Regulatory Requirements in Mind

New Webinar Announced on Stronger Clinical Document Authoring Workflows with Certara & TrialAssure

by Don McLean | September 2025

Posted in Blog, News

Read More

AI in Drug Development

TrialAssure’s Zach Weingarden Joins Other Pharmaceutical Industry Leaders to Present on the Future of AI in Drug Development at RAPS Convergence 2025

by Don McLean | August 2025

Posted in Events, News

Read More

Scalable Medical Writing AI

The First Step Toward Scalable Medical Writing AI

by Don McLean | July 2025

Posted in Blog

Read More

Design for Transparency

What Sponsors Gain by Embracing the Design for Transparency Concept

by Don McLean | July 2025

Posted in Blog

Read More

AI for clinical trial registration using TrialAssure REGISTRY

TrialAssure Enhances REGISTRY Platform with AI-Powered Protocol Parsing to Streamline Global Clinical Trial Registration

by Don McLean | June 2025

Posted in Blog, News

Read More

GenAI That Works: How Partnerships Outperform Internal Builds in Pharma | TrialAssure

Why Internal GenAI Builds in Pharma Often Fall Short

by Don McLean | June 2025

Posted in Blog

Read More

Building a Data Sharing Mindset with 5 Steps to Streamline Anonymization Early in Clinical Trials TrialAssure

Building a Data Sharing Mindset with 5 Steps to Streamline Anonymization Early in Clinical Trials

by Don McLean | May 2025

Posted in Blog

Read More

DIA Europe 2025

AI Takes Center Stage at DIA Europe 2025 in Basel

by Staff Writer | May 2025

Posted in Blog

Read More

Get in Touch